COVID-19 and immunomodulation treatment for women with reproductive failures

Kwak‐Kim, Joanne; Ota, Kuniaki; Sung, Nak‐Ju; Huang, Changsheng; Alsubki, Lujain; Lee, Sungki; Han, Jae Won; Han, Ae Ra; Yang, Xiuhua; Saab, Wael; Derbala, Y. S.; Wang, Wen Juan; He, Qin; Liao, Aihua; Takahashi, Toshifumi; Cavalcante, Marcelo Borges; Barini, Ricardo; Bao, Shihua; Fukui, Atsushi; Lédée, Nathalie; Coulam, Carolyn B.

doi:10.1016/j.jri.2020.103168

Cited by 12 publications

(12 citation statements)

References 97 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[36,37] Convalescent plasma: The concept of virus-neutralizing antibody effects was said by many scientific published materials and based upon collection of IgG antibodies from recently recovered COVID-19 patients who appeared to have confirmed high IgG levels in their plasma (more than 1: 160). [38] The only known limitation is to restrict the plasma donation locally due to the presence of several COVID-19 viral strains across different geographical areas. Donated plasma containing IgG antibodies could provide a passive immunity through cytotoxic and phagocytic properties which was proved to support patients with moderate and severe COVID-19 illness when combined with antivirals.…”

Section: Cross-reactivity Of Immune Responsementioning

confidence: 99%

“…Donated plasma containing IgG antibodies could provide a passive immunity through cytotoxic and phagocytic properties which was proved to support patients with moderate and severe COVID-19 illness when combined with antivirals. [38] The amount and duration of convalescent plasma therapy may depend on the viral load and severity of COVID-19 infection. It could be used in prevention and/ or treatment even in small amounts.…”

Section: Cross-reactivity Of Immune Responsementioning

confidence: 99%

See 1 more Smart Citation

Speculations of Immunotherapy in COVID-19 Patients with Practical Applications During Childhood and Pregnancy

Al-Momen

Jasim

Al-Ameri

2020

Al-Kindy Col. Med. J

View full text Add to dashboard Cite

The rapid spread of novel coronavirus disease(COVID19) throughout the world without availablespecific treatment or vaccine necessitates alternativeoptions to contain the disease. Historically, childrenand pregnant women were considered high-riskpopulation of infectious diseases but rarely have beenspotlighted nowadays in the regular COVID-19updates, may be due to low global rates of incidence,morbidity, and mortality. However, complications didoccur in these subjects affected by COVID-19. Weaimed to explore the latest updates ofimmunotherapeutic perspectives of COVID-19patients in general population and some added detailsregarding pediatric and obstetrical practice.Immune system boosting strategy is one of therecently emerging issues allowing the body defensemechanism to produce virus-neutralizing antibodies tocounteract the viral impacts on multiple organdamage. Measles vaccination (which is universallyused for children in many countries, butcontraindicated during pregnancy) could urge thebody to produce these antibodies which may applytheir effects through cross-reactivity of measlesvaccine and COVID-19 antigenic proteins. Inaddition, intravenous immunoglobulin andconvalescent plasma could have such neutralizingantibody effect leading to clinical improvement andviral elimination. Pediatric and obstetrical experiencehas appeared in previous publications.Human monoclonal antibodies are the futurepromising approach to treat and prevent COVID-19with the use of tocilizumab in recent studies. Pediatricdata are still in progress while no pregnancy ongoingtrials are planned up to date.The better understanding of the host antiviral responsemay pave the way to develop immunotherapeuticplans against COVID-19 in the near upcoming days.

show abstract

Section: Cross-reactivity Of Immune Responsementioning

confidence: 99%

Section: Cross-reactivity Of Immune Responsementioning

confidence: 99%

Speculations of Immunotherapy in COVID-19 Patients with Practical Applications During Childhood and Pregnancy

Al-Momen

Jasim

Al-Ameri

2020

Al-Kindy Col. Med. J

View full text Add to dashboard Cite

show abstract

“…Therefore, the management of hyper-coagulability in a pregnant woman infected with COVID-19 needs special attention, since COVID-19 can aggravate the thrombotic complications. Moreover, pregnant women with reproductive failure are at greater risk of severe SARS-COV-2 disease, as there are chances of developing acquired thrombophilia 45 . Low molecular weight heparin (LMWH) is a good option as an anticoagulant to treat pregnant women with reproductive failures 45 .…”

Section: Thrombophilic Complications In Pregnant Womenmentioning

confidence: 99%

“…Moreover, pregnant women with reproductive failure are at greater risk of severe SARS-COV-2 disease, as there are chances of developing acquired thrombophilia 45 . Low molecular weight heparin (LMWH) is a good option as an anticoagulant to treat pregnant women with reproductive failures 45 . However, further research on the thrombotic complications and its treatment options in pregnant women infected with SARS-CoV-2 is the need of the hour.…”

Section: Thrombophilic Complications In Pregnant Womenmentioning

confidence: 99%

Hematologic parameters in coronavirus infection (COVID-19) and their clinical implications

Waleed¹,

Sehar²,

Iftikhar³

et al. 2020

Discoveries (Craiova)

View full text Add to dashboard Cite

Coronaviruses are a class of enveloped RNA viruses that cause infections of the respiratory tract, characterized by fever, tiredness, dry cough, diarrhea, loss of smell or taste, chest pain and shortness of breath. Many patients with mysterious pneumonia were distinguished in December 2019 in Wuhan. The pneumonia of obscure origin was found to be ascribed to a novel coronavirus and described as novel coronavirus pneumonia (NCP). The Chinese authorities initially reported the wave of mysterious pneumonia on December 31st, 2019 and it was declared as an outbreak of international concern on January 30th, 2020. A systematic search of relevant research was conducted, and a total of 58 primary research articles were identified, analyzed, and debated to better understand the hematologic profile in COVID-19 (Coronavirus disease) infection and its clinical implications. All the findings in this article manifest a true impression of the current interpretation of hematological findings of the SARS-COV-2 disease. Pathophysiology of COVID-19 disease can be better interpreted by taking into consideration the hematologic parameters. Clinical implications of the hematologic profile of COVID-19 patients including cytokine storm, coagulation profile, and thrombophilic complications are under-recognized. Therefore, this review focuses on the coagulation profile, cytokine storm, and its treatment options. The role of pre-existing thrombophilia in COVID-19 patients and how it could result in the poor prognosis of the disease is also debated. The recent data suggests that hypercoagulability could be the potential cause of fatalities due to COVID-19. Potential effects of tocilizumab, metronidazole, and ulinastatin in suppressing cytokine storm may help to treat SARS-COV-2 infection. This review also highlights the significance of thrombophilia testing in SARS-CoV-2 patients depending on the clinical features and especially in pregnant women.

show abstract

“…Recently, an international collaboration of experts who have been working in the field of reproductive immunology debated the use of immunotherapies in patients with reproductive failures during the pandemic by COVID-19. The authors commented that due to possible transmission of SARS-CoV-2 via lymphocyte donors' blood and a lack of knowledge about the impact of LIT on the immune response in COVID-19 cases, the LIT should be discontinued until there is evidence of safety and a better understanding of the COVID-19 immune response [10].…”

Section: Dear Editormentioning

confidence: 99%

Reply to letter to the editor: “Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China”

Cavalcante

Sarno

Júnior

et al. 2020

Arch Gynecol Obstet

Self Cite

View full text Add to dashboard Cite

COVID-19 and immunomodulation treatment for women with reproductive failures

Cited by 12 publications

References 97 publications

Speculations of Immunotherapy in COVID-19 Patients with Practical Applications During Childhood and Pregnancy

Speculations of Immunotherapy in COVID-19 Patients with Practical Applications During Childhood and Pregnancy

Hematologic parameters in coronavirus infection (COVID-19) and their clinical implications

Reply to letter to the editor: “Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China”

Contact Info

Product

Resources

About